Leonteq Securities’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
Other funds holding NTLA
Leonteq Securities's NTLA Position: Q3 2026 in Review
Leonteq Securities increased its Intellia Therapeutics (NTLA) stake by 19% in Q3 2026, buying an estimated $8K and bringing the position to 3,929 shares worth $47.4K. The position accounts for ﹤0.01% of the portfolio, ranked #789.
Leonteq Securities first reported a position in NTLA in Q3 2021 and has held it in 21 quarters since. The position peaked at $511K in Q4 2025. 244 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.
- Leonteq Securities held 3,929 shares of Intellia Therapeutics worth $47.4K as of Q3 2026.
- Leonteq Securities bought 640 Intellia Therapeutics shares in Q3 2026, an estimated $8K.
- Intellia Therapeutics made up ﹤0.01% of Leonteq Securities's portfolio in Q3 2026, its #789 holding.
- Leonteq Securities first reported a position in Intellia Therapeutics in Q3 2021 and has held it in 21 quarters since.
- Leonteq Securities's Intellia Therapeutics position peaked at $511K in Q4 2025.
- 244 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.
Based on Leonteq Securities's 13F filing for Q3 2026, filed 29 Oct 2026.